clinical trial · NCT07181109
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskZilebesiranPlacebo
brief summary
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
started
Sep 22, 2025
primary completion
Sep 30, 2030
completion
Sep 30, 2030
last updated
Jun 12, 2026
official title
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol